Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Understanding your income needs for retirement at 55 is vital. Assess your financial situation to plan for a secure retirement.
16,389 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
MercadoLibre has faced a harsh year, sliding as investors fret about margins and investments. This guide explains why...
Memory prices are showing signs of life, and a small-cap memory company could ride the wave. This article explains wh...
As 2026 unfolds, investors face a choice between StubHub's fast-growing digital ticketing platform and Build-A-Bear's...
Copart director Daniel Englander recently sold 80,000 shares for about $2.2 million. With CPRT down roughly 40%, inve...
A significant stake in Clearwater Analytics has sparked renewed interest in the company’s SaaS-driven investment acco...
A New York-based issuer sells rated notes backed by a pool of bitcoin-backed consumer loans, signaling a milestone fo...
Gold has rallied about 73% over the past year as inflation jitters fade and risk-off trades surge. This report shows ...
A marquee collaboration turned cautionary tale. Explore how a failed merch deal unfolded, what it cost, and how to sh...
Bank of America reinstates Ford with a Buy rating and a $17 target, while Rivian is downgraded to Underperform with a...
A Texas Senate hopeful rides viral videos to a Democratic nomination, while Republicans mine his social media history...
Gold soars to $5,100 an ounce as major indices retreat and oil prices climb, signaling a shift toward hedges and new ...